Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 21OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × fosaprepitant × Clear all
NCT05509634 2023-10-27

Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors

Fujian Shengdi Pharmaceutical Co., Ltd.

Phase 3 Completed
754 enrolled

Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡